387 related articles for article (PubMed ID: 32540409)
1. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE
J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
3. Lung Cancer Driven by BRAF
Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
[TBL] [Abstract][Full Text] [Related]
4. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H; Feng J; Lu S; Huang J
Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
[TBL] [Abstract][Full Text] [Related]
5. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
7. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
8. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L; Yang P; Liu Y; Li J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M; Cascetta P; Planchard D
Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
[TBL] [Abstract][Full Text] [Related]
10. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
13. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
14. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
15. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Lin Q; Zhang H; Ding H; Qian J; Lizaso A; Lin J; Han-Zhang H; Xiang J; Li Y; Zhu H
J Transl Med; 2019 Aug; 17(1):298. PubMed ID: 31470866
[TBL] [Abstract][Full Text] [Related]
16. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
[TBL] [Abstract][Full Text] [Related]
17. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
18. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Noeparast A; Teugels E; Giron P; Verschelden G; De Brakeleer S; Decoster L; De Grève J
Oncotarget; 2017 Sep; 8(36):60094-60108. PubMed ID: 28947956
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
20. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Sakai T; Matsumoto S; Ueda Y; Shibata Y; Ikeda T; Nakamura A; Kodani M; Ohashi K; Furuya N; Izumi H; Nosaki K; Umemura S; Zenke Y; Udagawa H; Sugiyama E; Yoh K; Goto K
J Thorac Oncol; 2023 Nov; 18(11):1538-1549. PubMed ID: 37543207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]